Abliva AB Stock Deutsche Boerse AG

Equities

NTP

SE0002575340

Biotechnology & Medical Research

Delayed Deutsche Boerse AG Other stock markets 03:46:25 2024-07-17 am EDT			5-day change	1st Jan Change
0.0128 ^EUR	+0.79%		+70.67%	+4.07%

May. 30	Abliva Concludes Dosing in Mid-stage Study of Mitochondrial Disease Drug	MT
May. 30	Abliva AB Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease	CI

Financials

Sales 2024 *	-	Sales 2025 *	-	Capitalization	293M 27.92M 25.51M
Net income 2024 *	-128M -12.18M -11.13M	Net income 2025 *	-146M -13.89M -12.69M	EV / Sales 2024 *	-
Net cash position 2024 *	22M 2.09M 1.91M	Net cash position 2025 *	82M 7.8M 7.13M	EV / Sales 2025 *	-
P/E ratio 2024 *	-2.18 x	P/E ratio 2025 *	-1.81 x	Employees	6
Yield 2024 *	-	Yield 2025 *	-	Free-Float	88.06%

More Fundamentals * Assessed data

Chart Abliva AB

Duration

Period

Style

Dynamic Chart

Latest news about Abliva AB

Abliva Concludes Dosing in Mid-stage Study of Mitochondrial Disease Drug	May. 30	MT
Abliva AB Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease	May. 30	CI
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 23	CI
Transcript : Abliva AB - Special Call	May. 21
Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 23	CI
Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	Dec. 20	CI
EU Commission Grants Orphan Drug Designation to Abliva’s Mitochondrial Disease Drug Candidate; Stock Jumps	Dec. 14	MT
Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI
Abliva AB and Owl Therapeutics Enter into Licensing and Collaboration Agreement for NeuroSTAT in Traumatic Brain Injury	Nov. 14	CI
Abliva AB Achieves Important Milestone in the Ongoing FALCON Study	23-10-11	CI
Abliva Rises 28% on US FDA Fast Track Designation for Mitochondrial Disease Drug Candidate	23-09-04	MT
Abliva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18	CI
Abliva AB Announces First Patient Dosed in the Falcon Study	23-06-28	CI
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
Abliva AB Announces Resignation of Edwin Moses as Director	23-05-04	CI

More news

Latest transcript on Abliva AB

Abliva AB - Special Call

May. 21

More transcripts

Press releases Abliva AB

Amended number of shares and votes in Abliva AB (publ)	May. 31	AQ
Abliva Announces Completion of 24 Weeks of Dosing in Wave 1 of the FALCON Study of KL1333 in Primary Mitochondrial Disease	May. 30	AQ
Ablivas CEO to BioStock: "We remain on track for the interim analysis early in Q3"	May. 29	AQ
Resolutions from Annual General Meeting in Abliva AB (publ) on May 23, 2024	May. 23	AQ
Abliva : Interim Report January - March 2024	May. 23	PU

More press releases

Quotes and Performance

1 day	+0.79%
1 week	+70.67%
Current month	+146.15%
1 month	+60.00%
3 months	+64.10%
6 months	+10.34%
Current year	+4.07%

More quotes

Highs and lows

1 week

0.01

1 month

0.00

0.01

Current year

0.00

0.03

1 year

0.00

0.03

3 years

0.00

0.06

5 years

0.00

0.22

10 years

0.00

8.75

More quotes

Managers and Directors - Abliva AB

Managers	Title	Age	Since
Ellen Donnelly CEO	Chief Executive Officer	50	21-02-02
Eskil Elmér FOU	Founder	54	00-01-31
Catharina Jz Johansson DFI	Director of Finance/CFO	57	13-11-30

Members of the board	Title	Age	Since
David Laskow-Pooley CHM	Chairman	70	16-04-27
David Bejker BRD	Director/Board Member	49	17-04-26
Eskil Elmér FOU	Founder	54	00-01-31

More insiders

Quotes

Date	Price	Change
24-07-17	0.0128	+0.79%
24-07-16	0.0127	-5.22%
24-07-15	0.0134	-8.22%
24-07-12	0.0146	+3.55%
24-07-11	0.0141	+88.00%

Delayed Quote Deutsche Boerse AG, July 17, 2024 at 03:46 am EDT

More quotes

Company Profile

Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+23.64%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-15.68%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs

Abliva AB Stock Deutsche Boerse AG

Equities

NTP

SE0002575340

Biotechnology & Medical Research

Financials SEKUSDEUR

Latest transcript on Abliva AB

EPS Revisions

Annual profits - Rate of surprise

Financials